RPRX NASDAQ
Royalty Pharma plc
1W: -1.8%
1M: -9.4%
3M: +0.4%
YTD: +47.9%
1Y: +58.2%
3Y: +127.9%
5Y: +70.8%
$57.16
-0.47 (-0.82%)
Weekly Expected Move ±3.2%
$53
$55
$57
$59
$61
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Royalty Pharma (NASDAQ:RPRX) Stock: Insider Christopher Hite Sells 100,000 Shares
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Andra AP fonden Lowers Stock Holdings in Royalty Pharma PLC $RPRX
Analysts Set Royalty Pharma PLC (NASDAQ:RPRX) Price Target at $61.29
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Amgen drops on Novartis trial setback for heart therapy; BMO downgrades
At a glance: stocks gapping down premarket
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma
Quarterly Rebalance Ushers High-Quality Names Into GFLW
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Zealand gains $100M in funding from Royalty Pharma
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma reports second quarter 2026 results
Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Amundi Increases Stake in Royalty Pharma PLC $RPRX
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.
Chicago Partners Investment Group LLC Purchases New Position in Royalty Pharma PLC $RPRX
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week High – Should You Buy?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
RPRX or ACAD: Which Is the Better Value Stock Right Now?
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
Royalty Pharma to present at upcoming investor conferences
Earnings Scheduled For May 6, 2026
Royalty Pharma plc Q1 2026 Earnings Call Summary
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
Royalty Pharma reports Q1 results; raises FY26 outlook
Royalty Pharma reports first quarter 2026 results
Royalty Pharma reports first quarter 2026 results
Royalty Pharma Q1 2026 Earnings Preview
Charles River Gears Up for Q1 Earnings: What's in the Cards?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Royalty Pharma PLC (NASDAQ:RPRX) Receives $49.00 Average Price Target from Analysts
Asset Management One Co. Ltd. Sells 17,023 Shares of Royalty Pharma PLC $RPRX
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now
Royalty Pharma declares $0.235 dividend
Royalty Pharma Declares Second Quarter 2026 Dividend
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX
Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock
Royalty Pharma in $500M R&D funding collaboration with J&J
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX
Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd.
Brokerages Set Royalty Pharma PLC (NASDAQ:RPRX) Price Target at $48.67
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
Terrance Coyne Sells 34,791 Shares of Royalty Pharma (NASDAQ:RPRX) Stock
Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
Denali gains on FDA approval of lead asset
Moderna stands as the best performing large-cap healthcare stock YTD
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
Swiss Life Asset Management Ltd Has $4.03 Million Holdings in Royalty Pharma PLC $RPRX
Alpine Global Management LLC Makes New Investment in Royalty Pharma PLC $RPRX
Royalty Pharma Announces Expansion of Leadership Team
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High – Should You Buy?
Elo Mutual Pension Insurance Co Purchases 13,856 Shares of Royalty Pharma PLC $RPRX
Royalty Pharma PLC (NASDAQ:RPRX) Receives $48.67 Average PT from Analysts
APG Asset Management N.V. Sells 12,192 Shares of Royalty Pharma PLC $RPRX
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Citigroup Inc. Trims Stake in Royalty Pharma PLC $RPRX
Teva, Medincell granted FDA review for long-acting antipsychotic
Royalty Pharma: 2025 Financial Performance And Strategic Outlook
Royalty Pharma Q4 Earnings Call Highlights
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
Royalty Pharma Reports Q4 and Full Year 2025 Results
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS